The purpose of this study is to collect DNA, RNA, Serum, Plasma and CSF samples from donors with ALS that will be utilized to delineate vulnerability markers for the disease, enhance the understanding of treatment response and side effects and develop new targets for future drug development.
Amyotrophic Lateral Sclerosis (ALS) , Familial ALS , Sporadic ALS
Type of Intervention:
Study Chair(s)/Principal Investigator(s):
John Flax, MD (PrecisionMed)
Coordinating Center Contact Information
132 N Acacia Ave #1104
Solana Beach, California, 91942 United States
Full Study Summary:
This is a single or multiple visit study to evaluate clinical severity and collect DNA/RNA/SERUM/ PLASMA/CSF from donors with amyotrophic lateral sclerosis (ALS) and related disorders. Donors will have diagnostic as well as severity evaluating clinical rating scales. Donors who elect to return for additional visits will be seen every 4 months. Study visits consist of administration of rating scales, clinical data and blood + CSF collection.
At least 1 visit, but allowed to return for follow up visits if patient so chooses. Visits are conducted at treating physician’s clinic as a normal standard of care visit.
Estimated Study Completion Date:
01 / 01 / 2025
Posting Last Modified Date:
04 / 15 / 2021
Date Study Added to neals.org:
04 / 15 / 2021
Can participants use Riluzole?
Sharlin Health Neuroscience
Providence Brain and Spine Insititute
Austin Neuromuscular Center
Nerve and Muscle Center of Texas